Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 12/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10170480 | 0.88 | MCL1 (0.43) | PTGER1CYP1A2CYP2C9 | |
| SCHEMBL27741787 | 0.85 | SMN1; SMN2 (0.41) | BRD4PTGER1CYP1A2SMN1; SMN2STAT3 | |
| SCHEMBL10170473 | 0.83 | NOTUM (0.41) | PTGER1SMN1; SMN2RAB9ACYP2C9 | |
| SCHEMBL10315902 | 0.82 | MCL1 (0.45) | PTGER1CYP1A2 | |
| SCHEMBL10315951 | 0.80 | KDM4E (0.43) | RAB9A | |
| SCHEMBL10170483 | 0.80 | HSP90AA1 (0.52) | — | |
| SCHEMBL13328118 | 0.79 | HSP90AA1 (0.53) | PTGER1RAB9APTPN1 | |
| SCHEMBL3710065 | 0.79 | HSP90AA1 (0.47) | — | |
| SCHEMBL10170484 | 0.77 | HSP90AA1 (0.58) | — | |
| SCHEMBL3305910 | 0.77 | HSP90AA1 (0.45) | RAB9AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8816070-B2 | Triazole derivative as an HSP 90 inhibitor | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| EP-2023922-B1 | TRIAZOLE DERIVATIVES II | MERCK PATENT GMBH (DE) | 2012-07-11 | — | — | EP | disclosed |
| US-8119795-B2 | Triazole derivatives II | MERCK PATENT GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20100113542-A1 | TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR | MERCK PATENT GESELLSCHAFT (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100022540-A1 | TRIAZOLE DERIVATIVES II | MERCK PATENT GESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| EP-2023922-A2 | TRIAZOLE DERIVATIVES II | Merck Patent GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007134678-A2 | TRIAZOLE DERIVATIVES II | MERCK PATENT GMBH (DE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022540-A1 | TRIAZOLE DERIVATIVES II | HSP90AB1, HSP90AA1, HSP90AB2P | BRD4 846/4885PTGER1 2508/4885CYP1A2 179/4885 |
| US-20100113542-A1 | TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR | HSP90AB1, HSP90AB2P, HSP90AA1 | BRD4 153/4885PTGER1 4068/4885CYP1A2 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.